Back to search results

Enhanced Recovery and Chronic Pain for Total Knee Arthroplasty

This study is looking at ways to reduce pain and opioid use after total knee replacement surgery. It's testing if a continuous infusion of 0.2% ropivacaine through a catheter (a thin tube) placed near the knee can extend pain relief beyond 24-48 hours, compared to a single injection. The main goal is to see if this continuous infusion reduces the amount of opioid pain medication you need in the first 24-48 hours after surgery. This could also help prevent "rebound pain" (severe pain when the nerve block wears off) and allow you to start moving sooner. We are looking for 64 participants, aged 18-75, who are having a total knee replacement for osteoarthritis and can speak English. The current recruitment status is unclear.

Study design
This is an interventional study where 64 participants will be randomly assigned to receive either a continuous infusion of ropivacaine or a sham catheter with no infusion.
What's involved
You will be asked to use a special app to communicate with a pain doctor while the catheter is in place. You will also have follow-up appointments for up to 6 months after your operation.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 6 months post-operation.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05981105

Enhanced Recovery After Major Surgery and Chronic Pain for Total Knee Arthroplasty

Recruiting
NAAges 18–75Interventional
Hospital for Special Surgery, New York
~64 participants
Updated 2026-01-15 on ClinicalTrials.gov
What's tested:ambIT pump with catheterambIT pump with sham catheter

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Opioid consumption at 24-48 hours
Measured over from 24 hours to 48 hours

Conditions

Chronic Pain
Opioid Use
Adductor Canal Block
Total Knee Arthroplasty

Explore related trials

Osteoarthritis

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Stavros Memtsoudis, MD/PhD · PRINCIPAL_INVESTIGATOR · Hospital for Special Surgery, New York
  • Jashvant Poeran, MD/PhD · STUDY_DIRECTOR · Hospital for Special Surgery, New York

Who to contact

Pa Thor, PhD
[email protected]
646-797-8535
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with osteoarthritis scheduled for a primary total knee arthroplasty with a participating surgeon
Age 18 to 75 years
Planned use of regional anesthesia
Ability to follow study protocol
English speaking (secondary outcomes include questionnaires validated in English only)
Patients of participating surgeons: Drs. Mayman, Jerabek, Westrich, Su, Della Valle, Alexiades
Lives within one hour of the hospital
Has a smartphone

Exclusion

Hepatic or renal insufficiency
Younger than 18 years old and older than 65
Patients undergoing general anesthesia
Allergy or intolerance to one of the study medications
BMI \> 40
Diabetes
ASA of III,IV
Chronic gabapentin/pregabalin use (regular use for longer than 3 months)
PCS \> 30
Chronic opioid use (taking opioids for longer than 3 months, or daily oral morphine equivalent of \>5mg/day for one month)
Patients with severe valgus deformity or flexion contracture
Patients unable to follow home catheter instructions and unwilling to go home with an infusing catheter
Patients who have no home caregivers in the event if a catheter is to be sent home with the patient
Patients with planned stay at rehab facility

What this trial measures

  • Opioid consumption at 24-48 hoursfrom 24 hours to 48 hours

    The cumulative opioid consumption 24-48 hours post block administration. Measured in morphine milligram equivalents per day. Although collected over a period of time, the total amount will be summed and the average will be reported.